Discovery Capital Management Cut Esperion Therapeutics Ne (ESPR) Holding; 6 Analysts Covering PG&E (PCG)

April 17, 2018 - By Marie Mckinney

Discovery Capital Management Llc decreased Esperion Therapeutics Inc Ne (ESPR) stake by 39.32% reported in 2017Q4 SEC filing. Discovery Capital Management Llc sold 307,884 shares as Esperion Therapeutics Inc Ne (ESPR)’s stock rose 22.41%. The Discovery Capital Management Llc holds 475,175 shares with $31.29M value, down from 783,059 last quarter. Esperion Therapeutics Inc Ne now has $2.03B valuation. The stock increased 2.64% or $1.9702 during the last trading session, reaching $76.4602. About 334,782 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 17, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Among 16 analysts covering PG&E Corporation (NYSE:PCG), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. PG&E Corporation had 51 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, July 13 by BMO Capital Markets. On Friday, April 21 the stock rating was maintained by Jefferies with “Buy”. Morgan Stanley upgraded the stock to “Overweight” rating in Tuesday, January 26 report. Barclays Capital maintained the shares of PCG in report on Wednesday, September 2 with “Overweight” rating. Goldman Sachs upgraded the shares of PCG in report on Wednesday, January 27 to “Buy” rating. The stock has “Hold” rating by Wells Fargo on Monday, February 12. Barclays Capital maintained the stock with “Overweight” rating in Friday, March 18 report. The stock of PG&E Corporation (NYSE:PCG) earned “Buy” rating by Deutsche Bank on Monday, April 18. Barclays Capital maintained PG&E Corporation (NYSE:PCG) on Friday, September 22 with “Overweight” rating. The firm has “Buy” rating by J.P. Morgan given on Monday, October 16. See PG&E Corporation (NYSE:PCG) latest ratings:

16/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $59 New Target: $63 Maintain
10/04/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $50 New Target: $51 Maintain
05/04/2018 Broker: Mizuho Rating: Hold New Target: $46.0000 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $57 New Target: $50 Maintain
12/02/2018 Broker: Wells Fargo Rating: Hold New Target: $45.0 Maintain
02/02/2018 Broker: UBS Rating: Neutral New Target: $48 Initiates Coverage On
22/01/2018 Broker: Citigroup Rating: Hold New Target: $45.0 Maintain
02/01/2018 Broker: Goldman Sachs Old Rating: Buy New Rating: Neutral Downgrade
02/01/2018 Broker: Guggenheim Old Rating: Neutral New Rating: Sell Downgrade
21/12/2017 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Downgrade

Investors sentiment decreased to 0.93 in Q4 2017. Its down 0.24, from 1.17 in 2017Q3. It is negative, as 97 investors sold PG&E Corporation shares while 174 reduced holdings. 109 funds opened positions while 142 raised stakes. 400.70 million shares or 2.67% less from 411.71 million shares in 2017Q3 were reported. Janney Montgomery Scott Limited Liability Corp holds 0% or 6,327 shares in its portfolio. Liberty Mutual Asset accumulated 22,151 shares. Gulf Bancorporation (Uk) Ltd has 161,428 shares for 0.09% of their portfolio. Public Employees Retirement Association Of Colorado, a Colorado-based fund reported 95,748 shares. Boston Private Wealth Limited Liability Corp reported 0.01% of its portfolio in PG&E Corporation (NYSE:PCG). Asset Mngmt One Com holds 844,567 shares. Old Mutual Investors (Uk) Limited stated it has 1% of its portfolio in PG&E Corporation (NYSE:PCG). Tompkins Fincl accumulated 120 shares. Andra Ap reported 183,300 shares stake. D E Shaw And reported 5.25 million shares or 0.32% of all its holdings. Earnest Prns Lc reported 0% in PG&E Corporation (NYSE:PCG). Ledyard Savings Bank holds 0% in PG&E Corporation (NYSE:PCG) or 611 shares. Credit Suisse Ag invested in 1.06 million shares or 0.04% of the stock. Fny Managed Accounts Llc reported 114 shares. Zimmer Prtn Limited Partnership accumulated 930,000 shares or 1.02% of the stock.

PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, transmits, delivers, and sells electricity and natural gas to residential, commercial, industrial, and agricultural clients primarily in northern and central California. The company has market cap of $24.07 billion. The companyÂ’s electricity distribution network consists of approximately 142,000 circuit miles of distribution lines, 59 transmission switching substations, and 606 distribution substations; and electricity transmission network comprises approximately 18,400 circuit miles of interconnected transmission lines and 92 electric transmission substations. It has a 14.54 P/E ratio. The Company’s natural gas system consists of approximately 42,800 miles of distribution pipelines, approximately 6,700 miles of backbone and local transmission pipelines, and various storage facilities.

The stock increased 2.35% or $1.07 during the last trading session, reaching $46.66. About 2.00 million shares traded. PG&E Corporation (NYSE:PCG) has declined 34.60% since April 17, 2017 and is downtrending. It has underperformed by 46.15% the S&P500.

Discovery Capital Management Llc increased Mbia Inc (NYSE:MBI) stake by 1.40 million shares to 3.17M valued at $23.17 million in 2017Q4. It also upped Eog Res Inc (NYSE:EOG) stake by 573,500 shares and now owns 778,500 shares. Grupo Supervielle S A was raised too.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 61 analyst reports since July 28, 2015 according to SRatingsIntel. Barclays Capital maintained the shares of ESPR in report on Wednesday, February 24 with “Overweight” rating. JMP Securities maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $67 target. The firm earned “Sell” rating on Monday, August 31 by Chardan Capital Markets. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Tuesday, September 29 with “Sell” rating. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. The firm has “Sell” rating by Chardan Capital Markets given on Friday, August 7. Credit Suisse upgraded the stock to “Neutral” rating in Monday, March 20 report. The company was upgraded on Wednesday, August 9 by Jefferies. On Wednesday, February 21 the stock rating was maintained by Needham with “Buy”. As per Monday, July 27, the company rating was maintained by Chardan Capital Markets.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.